The Notch pathway stabilizes sprouting angiogenesis by favoring stalk cells over tip cells at the vascular front. Because tip and stalk cells have different properties in morphology and function, their transcriptional regulation remains to be distinguished. Transcription factor Sox17 is specifically expressed in endothelial cells, but its expression and role at the vascular front remain largely unknown.
T he Notch pathway plays a pleiotropic role in vascular development such as angiogenic regulation and arterialvenous specification. Notch activation stabilizes growing vascular network by suppressing excessive tip cell formation and maintaining stalk cell property at the vascular front. [1] [2] [3] [4] [5] [6] In line with this, Notch inhibition by delta-like ligand 4 (Dll4) blockade induces excessive but nonfunctional sprouting in tumor angiogenesis, 7-9 becoming a potential therapeutic option for tumor vessels. Several genetic studies demonstrated that the Notch pathway is required for the formation of dorsal aorta and arterial specification of endothelial cells across vertebrate species. 1, [10] [11] [12] [13] [14] After activation by Notch ligands, the Notch intracellular domain released from Notch receptors translocates into nucleus and interacts with the transcription factor CBF1/RBP-J k /Suppressor of Hairless/ LAG-1. 15 By using this signaling pathway, Notch system plays a role mainly by regulating expression of its downstream target genes such as Hes and Hey, which regulate the expression of further downstream genes as transcription factors. In fact, Notch signaling regulates the transcription of arterial marker genes including ephrinB2 16 and a key player in sprouting angiogenesis, VEGFR2. 17 Although the study of Hey1/Hey2 double-null embryo showing no arterial endothelial marker expression identified Hey1 and Hey2 as transcription factors downstream of the Notch pathway in arterial fate determination, 11 transcription factors involved in Notch-mediated vascular stabilization have not been revealed yet. Although differential gene expression between tip and stalk cells has been fairly elucidated, [18] [19] [20] how the Notch pathway governs transcriptional regulation in tip-stalk specification remains incompletely understood. such as endoderm organogenesis, fetal hematopoiesis, and vascular formation. [21] [22] [23] Interestingly, Sox7 and Sox18, other members of Sox F subgroup, are necessary for arterial specification in zebra fish [24] [25] [26] and lymphatic emergence in mouse, 27 implicating Sox F members in cell fate determination during vascular development. Recently, it has been revealed that Sox F members can regulate arterial Dll4 expression by binding to enhancer region of Dll4, 28 and Sox17 is indispensable for arterial specification in mouse vascular development by regulating the expression of Dll1, Dll4, and Notch4, key elements of the Notch pathway. 29 These studies identified Sox17 as an upstream regulator of the Notch pathway in arterial specification. However, the role of Sox17 in sprouting angiogenesis during vascular development has not been well studied, although the compound heterozygosity of Sox17 and Sox18 results in abnormal heart and vascular development. 30 A recent study elucidating the proangiogenic role of Sox17 in tumor angiogenesis 31 suggests that Sox17 might play a proangiogenic role in vascular development. Furthermore, how Sox17 interacts with Notch signaling in sprouting angiogenesis remains unclear.
In this study, we investigated that Sox17 is expressed in endothelial cells at the vascular front and promotes sprouting angiogenesis in vascular development using Sox17 genetic mouse models. We found that Sox17 expression is reduced in the stalk cells, whereas it is robust in the tip cells. By gain and depletion of Notch activity, we unveiled that the Notch pathway inversely regulates Sox17 expression in sprouting angiogenesis. Taken together, our findings establish the reduced Sox17 expression as a key mechanism for Notch-mediated vascular stabilization.
Methods
An expanded Methods section can be found in the Online Supplement.
Mutant Mice
For inducible Sox17 deletion and N1ICD overexpression in endothelial cells, Sox17 fl/fl and Gt(ROSA)26Sor tm1(Notch1)Dam/J mice were crossed with Cdh5(PAC)-CreER T2 transgenic mice, respectively. For endothelial-specific Sox17 deletion in embryonic development, Sox17 gfp/fl mice were crossed with Tie2-Cre transgenic mice. For inducible Sox17 overexpression in endothelial cells, Tet-O-Sox17 mice were interbred VE-cadherin-tTA mice. The administrations of tamoxifen and doxycycline were performed as described. [31] [32] [33] All animal experiments were approved by the Animal Care Committee of Korea Advanced Institute of Science and Technology.
Histology and Tissue Immunofluorescence
Cells and embryonic tissues (in 2% paraformaldehyde for 60 minutes), tumor tissues (in 1% paraformaldehyde for 60 minutes), hindbrain tissues (in 4% paraformaldehyde for 40 minutes), and extracted eyeballs (in 4% paraformaldehyde for 20 minutes) were fixed at 4°C and prepared for either whole mount or cryosection. For immunofluorescence, all samples were washed in PBS, blocked in PBS containing 0.1% Triton X-100 with 5% donkey serum, incubated with primary and fluorescently labeled secondary antibodies, counterstained with DAPI (4'6-diamidino-2-phenylindole) or Hoechst33258, and finally mounted in Vectashield (Vector Laboratories). Immunofluorescent images were acquired using Zeiss LSM510 confocal fluorescence microscope.
Embryonic Stem Cell Culture and Endothelial Differentiation
Mouse embryonic stem cell (ESC) lines were derived from Sox17 fl/fl blastocysts in a standard manner as described. 34 Sox17-null ESC line was obtained by adenoviral Cre delivery to the Sox17 fl/fl ESC line. ESC lines were maintained on mouse embryonic fibroblast feeders in DMEM containing 15% fetal bovine serum and leukemia inhibitory factor. Endothelial cells were induced as described. 35 Briefly, ESCs were cultured in the absence of leukemia inhibitory factor. After 4.5 to 5.0 days, fetal liver kinase 1-positive mesodermal precursor cells were purified using AutoMACS Pro Separator (Miltenyi) and plated onto 0.1% gelatin-coated dish in α-minimum essential medium with 10% fetal bovine serum in the presence of 50 ng/mL vascular endothelial growth factor-A165 (R&D) for 4 days.
In Vitro Modulation of Notch Signaling
For in vitro activation of Notch signaling, human umbilical vein endothelial cells were transfected with EF.hICN1.CMV.GFP vector (17623, Addgene) containing human Notch1 intracellular domain or EF.CMV.RFP vector (17619, Addgene) as a negative control. Twentyfour hours after transfection, cells were collected for immunoblotting or transcript analysis. Alternatively, human umbilical vein endothelial cells were plated on culture dishes coated with Dll4 (R&D) or BSA as a negative control for timed Notch activation. Cells were collected at the indicated time points for biochemical and transcriptional analyses. For in vitro inhibition of Notch signaling, human umbilical vein endothelial cells were treated with 10 μmol/L DAPT (N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butylester) dissolved in dimethylsulfoxide or equal amount of dimethylsulfoxide as a negative control. After 12 hours, cells were harvested for analysis.
Flow Cytometry Analysis and Cell Sorting
Differentiated cells were dissociated, incubated with antibodies, and analyzed by fluorescence-activated cell sorter AriaII (Beckton Dickinson). Dead cells were stained using 7-aminoactinomycin D (Invitrogen) and excluded for analysis. Tumor endothelial cells were purified as described. 31 Briefly, tumor tissues were dissociated and incubated with antibodies. After enrichment using AutoMACS Pro Separator (Miltenyi), tumor endothelial cells (CD31 + CD45 − Ter119 − ) were purified using fluorescence-activated cell sorter AriaII, and cell purity was checked to be >95%.
Statistics
Values are reported as mean±SD unless otherwise indicated. Significant differences between means were determined by ANOVA followed by 2-tailed Student-Newman-Keuls test. Statistical significance was set at P<0.01 or P<0.05.
Results

Sox17 Promotes Sprouting Angiogenesis in Embryonic Vascular Development
We examined Sox17 expression in sprouting angiogenesis by immunostaining embryonic vessels. We detected robust Sox17 staining only in the nuclei of endothelial cells of angiogenic capillary vessels ( Figure 1A ) as well as in arterial endothelial cells (Online Figure IA ), suggesting the role of Sox17 in sprouting angiogenesis. To characterize the role of endothelial Sox17 in vascular development, we analyzed vascular phenotypes in mutant embryos (Tie2-Cre Sox17 GFP/fl ), of which Sox17 alleles had been excised from endothelial cells by Tie2-Cre. Mutant embryos died around embryonic day 11.5 with vascular defects and growth retardation ( Figure 1B ). Mature dorsal aorta successfully formed in control embryos, but mature vessels were rare in Sox17-deficient embryos (Online Figure IB) . In contrast to a well-branched patterning of control vessels, Sox17-deficient vessels were less branched in the head and trunk ( Figure 1B ) and frequently remained as primary plexuses (Online Figure IC) .
To analyze sprouting angiogenesis more precisely, we examined blood vessels in embryonic day 10.5 hindbrain as a standard angiogenesis model during embryonic development. 36 Control vessels sprouted perpendicularly from perineural vascular plexus toward the ventricular zone and then formed capillary plexus by horizontal sprouting at subventricular layer. However, Sox17-deficient vessels failed to sprout from perineural vascular plexus ( Figure 1C -1E). Sprouting angiogenesis was also reduced in Sox17-deficient yolk sac vessels compared with controls ( Figure 1F ). Conversely, Sox17 overexpression in endothelial cells induced excessive angiogenesis as shown by increased vascular branching and more vascular sprouts in hindbrain and yolk sac relative to controls ( Figure 1G ). In addition, it led to the endothelial cells failing to form functional vessels as shown by defective lumen formation ( Figure 1H ) and remarkably less erythrocytes within yolk sac vessels in contrast to controls (Online Figure ID) . These findings indicate that endothelial Sox17 is indispensable for proper angiogenesis in embryonic vascular development and suggest that proper Sox17 expression is crucial for stabilized vessel formation.
Sox17 Promotes Sprouting Angiogenesis in Postnatal Vascular Development
Because retinal angiogenesis is an important angiogenic event after birth, we further studied the expression and role of Sox17 in postnatal retinal vessels. Sox17 was specifically detected in endothelial cells but not in pericytes of retinal vessels (Online Figure IIA) . Deletion of endothelial Sox17 in Cad5-CreER T2 Sox17 GFP/fl pups resulted in reduced radial extensions and vascular defects with a high variation, ranging from reduced vascular branching in moderate cases to an improperly organized vascular network with remarkably few tip cells and defective hierarchy formation in severe cases (Online Figure IIB and IIC). To exclude a potential long-term effect of Sox17 haploinsufficiency, we analyzed vascular changes in retinal angiogenesis by treating Cad5-CreER T2 Sox17 fl/fl pups with tamoxifen. Significant declines in radial extension, vascular branching, and tip cell number were found in Sox17-deficient vessels ( In line with its supportive role in tip cell formation at the vascular front, nuclear Sox17 was robustly detected in tip cells, but its expression was markedly reduced in stalk cells ( Figure 2I-2K ). This result suggests that Sox17 expression is regulated in tip-stalk specification.
Sox17 Destabilizes Endothelial Cells and Upregulates Tip Cell Preferential Genes
To understand the cellular mechanism by which Sox17 regulates the angiogenic process, we recapitulated vascular development by differentiating Sox17-null ESCs toward the endothelial lineage. Control and Sox17-null ESCs showed no appreciable difference in loss of pluripotency, emergence of mesodermal precursor cells, and endothelial generation (Online Figure IIIA-IIID) . These results suggest that Sox17 is dispensable for the emergence of endothelial population during early vascular development. In contrast, Sox17 deletion changed the behaviors of differentiated endothelial cells. Control endothelial cells had obvious destabilized junctional distribution of vascular endothelial cadherin and β-catenin, stellate stress fibers with cortical actin disassembly, and abundant lamellipodia and microspikes at the periphery; however, Sox17-null endothelial cells had linear junctional colocalization of vascular endothelial cadherin and β-catenin, considerable cortical bundles at the periphery, and few cellular protrusions ( Figure 3A ). Of note, ≈40% of cells within control endothelial colonies compared with only 17% of cells within Sox17-null endothelial colonies migrated freely between the center and peripheral regions, indicating reduced positional exchanging in Sox17-deficient endothelial cells ( Figure 3B and 3C). In addition, Sox17-null endothelial cells migrated ≈25% more slowly compared with controls ( Figure 3D ). These results indicate that Sox17 deletion reduces cell migratory behavior by stabilizing endothelial junctions and cytoskeletal structures. Interestingly, Sox17-deficient hyaloid vessels showed a substantially delayed regression, suggesting increased vascular stability by Sox17 deletion in postnatal vascular remodeling (Online Figure IVA) . Conversely, Sox17 overexpression in endothelial cells induced vascular destabilization as is shown by reduced vascular endothelial cadherin at endothelial junctions and impaired structural integrity in yolk sac vessels (Online Figure IVB and IVC) . These findings suggest that Sox17 might have a vascular destabilizing role during vascular remodeling and that Sox17 expression should be properly regulated during vascular development.
To gain insight into the molecular events underlying Sox17mediated vascular changes, we analyzed the expression of several angiogenic regulators in Sox17-silenced endothelial cells. Among several genes upregulated in tip cells relative to stalk cells, [18] [19] [20] the expression of Ang2, PDGFB, Apelin, ESM1, Dll4, and VEGFR2 was significantly decreased in Sox17-silenced endothelial cells at the transcript level, whereas Sox17 knockdown did not change the expression of VEGFR1 and Jag1, which are preferentially expressed in stalk cells 32, 37 ( Figure 3E ). We confirmed decreased Ang2 expression at the vascular front of Sox17-deficient retinal vessels at the protein level compared with control vessels ( Figure 3F ). This finding suggests that Sox17 might promote angiogenesis by increasing 
Notch Pathway Inhibits Angiogenesis by Reducing Sox17 Expression
Given the predominant role of the Notch pathway in tip-stalk determination 15, 32, 38 and differential Sox17 expression between tip and stalk cells ( Figure 2I-2K) , we explored whether the Notch pathway might regulate Sox17 expression in endothelial cells. Nuclear Sox17 declined specifically in endothelial cells successfully transfected with exogenous Notch1 intracellular domain (N1ICD), whereas mock-transfected or nontransfected endothelial cells robustly expressed Sox17 (Figure 4A and 4B). This result indicates that the Notch pathway can regulate Sox17 expression in a cell-autonomous manner. Furthermore, activated Notch signaling by gain of N1ICD in endothelial cells substantially repressed Sox17 expression at the vascular front, as well as tip cell number and branching in postnatal retinal vessels ( Figure 4C ). Conversely, inhibition of endogenous Notch activity by blocking Dll4, a vascularspecific Notch ligand, increased Sox17-expressing endothelial cells together with hyperbranching ( Figure 4D ). This result indicates that the Notch pathway suppresses Sox17 expression in endothelial cells at the vascular front during postnatal retinal angiogenesis. We also observed an inhibitory effect of Notch activity on Sox17 expression in tumor angiogenesis as shown by stronger Sox17 staining in Lewis lung carcinoma tumor vessels on Dll4 blockade compared with control IgG treatment ( Figure 6I) .
To characterize the functional involvement of Sox17 in Notch signaling, we studied the vascular effect of the Notch pathway in retinal angiogenesis of mutant pups lacking endothelial Sox17. Anti-Dll4 antibody induced hypersprouting and hyperdense vascular network in controls but did not result in increased filopodia number and vascular density in Sox17-deficient vessels ( Figure 5A-5C ). The angiogenic effect of Dll4 blocking on tumor angiogenesis was also significantly reduced in Sox17-deficient tumor vessels ( Figure 5D-5F) . These findings indicate that the angiogenic effect of Notch inhibition significantly depends on Sox17.
Notch Pathway Downregulates Sox17 Expression Mainly at the Post-Transcriptional Level
We then studied the mechanism for reduced Sox17 expression by Notch signaling in primary endothelial cells. Notch activation by N1ICD overexpression reduced Sox17 by 80% ( Figure 6A ), whereas Notch inactivation by the γ-secretase inhibitor DAPT increased Sox17 by 3.2-fold at the protein level ( Figure 6E) . In contrast, Notch pathway did not change Sox17 expression at the transcript level, although some known Notch downstream genes were transcriptionally regulated ( Figure 6B and 6F ). In addition, the change in Sox17 expression by Notch modulation was found at the protein level but not at the mRNA level in endothelial cells from both postnatal lung ( Figure 6C, 6D , 6G, and 6H) and tumors ( Figure 6I and 6J). These results indicate that Notch signaling inversely regulates Sox17 expression mainly at the post-transcriptional level.
To further specify how Notch activation decreases Sox17 protein levels, we established Notch activation in endothelial cells by Dll4 coating, which successfully increased the expression of several well-known Notch downstream genes ( Figure 7A ). Sox17 protein gradually decreased over 36 hours almost to a nondetectable level under Notch activation ( Figure 7B) , whereas Sox17 mRNA level was moderately reduced ( Figure 7C ), further indicating that Notch activity mainly affects Sox17 protein levels. Expression of a certain protein can be decreased at the post-transcriptional level mainly by reducing protein synthesis and increasing protein degradation. Because of the emerging significance of protein turnover in angiogenic regulation, 39, 40 we examined whether Notch activation can destabilize Sox17. On blocking translation by cycloheximide treatment, Sox17 degradation was modestly reduced in Notch-activated endothelial cells but was not statistically significant ( Figure 7D and 7E) , implying that reduced Sox17 protein level by Notch activity might not be achieved simply by increasing Sox17 protein degradation. However, we could not exclude the possibility of the requirement of a new protein synthesis for the Notchmediated Sox17 degradation. Whether the Notch pathway can interfere with Sox17 protein synthesis requires further investigation.
Discussion
Transcription factors play an important role in endothelial emergence and arterial-venous specification during vascular development 41, 42 ; however, their roles and significance in sprouting angiogenesis remain elusive. Here, using Sox17 loss-and gain-of-function mouse models, we demonstrate that transcription factor Sox17 promotes sprouting angiogenesis in vascular development. Sox17 is dispensable for the generation of endothelial cells at the initial stage of vascular development as shown by the existence of primitive capillary plexus in Sox17-deficeint embryos and successful endothelial differentiation from Sox17-null ESCs. In contrast, Sox17-deficient vessels show reduced sprouting angiogenesis in embryo hindbrain and postnatal retina. Consistent with this vascular defect, Sox17 is robustly expressed in endothelial cells at the vascular front where sprouting angiogenesis is active. In addition, we observed more stabilized adherens junctions, quiescent arrangement of cytoskeletal structures, and less motile cellular processes in endothelial cells derived from the Sox17-null ESC line, elucidating Sox17-mediated destabilization of endothelial cells as a critical process for proper angiogenesis. However, predominant Sox17 expression in arterial endothelial cells 43 and loss of arterial identity in Sox17-deficient vessels 29 reported in previous studies indicate that Sox17 has an additional regulatory role in arterial-venous specification. Taken together, Sox17 contributes to several processes of vascular development in a context-dependent manner after the onset of endothelial differentiation.
Although Corada et al 29 reported the indispensable role of Sox17 in mouse vascular development that is largely similar to our study here, the increased vascular sprouting of Sox17deficient retinal vessels in their work is contradictory with the reduced retinal angiogenesis after Sox17 deletion in our work. We found reduced vascular sprouting by Sox17 deletion in embryonic angiogenesis as well as postnatal retinal angiogenesis. Furthermore, Sox17 overexpression induced vascular sprouting in both embryonic and postnatal angiogenesis, indicating the proangiogenic function of Sox17 in vascular development. Consistent with these findings, the proangiogenic role of Sox17 was reported in other vascular contexts such as Norrin/Fz4/Lrp-mediated retinal angiogenesis 44 and tumor angiogenesis. 31 Although the same Cre line has been used in both studies, its Cre activity might be affected during mouse maintenance by unidentified mechanisms including epigenetic modifications. In addition, Sox17 function might be influenced by genetic background. Uemura et al 45 reported that Sox17 haplodeficiency resulted in bile duct malformation in C57BL/6 background compared with mixed genetic backgrounds. Phenotypic variability that may potentially be influenced by genetic background and efficiency of Cre-mediated deletion might complicate the analyses in Sox17-deficient retinal vessels. Hypersprouting of Sox17-deficient retinal vessels in the article by Corada et al 29 might be induced by Dll4 downregulation that is observed after Sox17 silencing in endothelial cells since Dll4 haploinsufficiency stimulates retinal angiogenesis. 4, 5 Notch activation in endothelial cells at the vascular front is essential for the acquisition of stalk cell property, but its downstream transcriptional regulation remains unclear. Our study reveals that the Notch pathway inhibits Sox17 expression and subsequently suppressed Sox17 expression reduces the expression of several genes preferentially expressed in tip cells. In line with this, Sox17 expression is reduced in stalk cells relative to tip cells. Furthermore, Sox17 expression is functionally required for excessive sprouting angiogenesis of retinal vessels by Notch inactivation. Taken together, these findings suggest that reduced Sox17 expression in stalk cells could be a responsible mechanism for Notch-mediated stalk cell specification. Furthermore, Notch regulation of Sox17 expression might play a vascular stabilizing role for functional vascular network formation by inhibiting excessive Sox17 expression. Sox17 overexpression induced severe vascular destabilization in yolk sac, leading to defective lumen formation and inefficient erythrocyte circulation. Interestingly, the Dll-Notch system is a fundamental signaling pathway conserved in various kinds of cell type, but how this common system induces different biological phenomena remains elusive. Our findings suggest that the Notch pathway might use Sox17 as a specific mediator in endothelial cells to regulate specialized downstream genes for vascular stabilization.
Although the article by Corada et al 29 is not supportive of the possibility that the Notch pathway is upstream of Sox17 expression, their data do not contradict with our observations such as the little change of Sox17 transcript level by the modulation of Notch activity. We observed that Notch activity can change Sox17 protein level at vascular front as well as in cultured endothelial cells, whereas Corada et al 29 found little change in Sox17 protein level mainly in arteries by Notch activity. However, they elucidated that Sox17 plays a regulatory role as an upstream transcription factor of some Notch ligands and Notch receptors essential for arterial determination. They also found that Sox17 is highly expressed in arterial endothelial cells and is required for the acquisition and maintenance of arterial identity in mouse vascular development. Together with our findings, these studies suggest that Sox17 can interact with the Notch pathway in different ways depending on the vascular context.
In general, transcriptional regulation is a cardinal mechanism of Notch signaling. In contrast, we show that Notch signaling regulates endothelial Sox17 expression mainly at the post-transcriptional level by gain and depletion of Notch activity. In line with post-transcriptional control of vascular endothelial growth factor receptor 3 levels by the Notch pathway in postnatal retinal angiogenesis, 46 our findings describe that the Notch pathway can control angiogenic regulators at the posttranscriptional level. However, we do not exclude the possibility that the Notch pathway can regulate the transcription of Sox17 in some contexts. Further investigation will reveal underlying molecular mechanisms.
The Notch pathway regulates tumor angiogenesis as well as developmental angiogenesis. [7] [8] [9] We previously found that Sox17 promotes tumor angiogenesis. 31 In this report, in addition to postnatal retinal angiogenesis, we found that Notch inhibition by Dll4 blockade induces excessive tumor angiogenesis at least partly by increasing Sox17 expression. This result suggests that the Notch pathway can use Sox17 to control angiogenesis in both developmental and tumor contexts and implicates Sox17 in recent therapeutic approaches using Dll4 blocking antibodies. 47, 48 Collectively, we elucidate that Sox17 plays a role as a proangiogenic regulator in vascular development, and the downregulation of Sox17 expression in stalk cells is important for proper vascular patterning. Here, we establish the Notch pathway as an upstream regulatory mechanism of Sox17 expression in sprouting angiogenesis.
